Joel Roger Gingerich

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Karim Fizazi, Josep M. Piulats, M. Neil Reaume et al. · New England Journal of Medicine · 2023 · 414 citations · Full text

Medicine, Oncology, Pharmacology +15

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial

Matti Annala, Simon Fu, Jack V. W. Bacon et al. · Annals of Oncology · 2021 · 71 citations

Medicine, Oncology, Pharmacology +14

A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer

Evan Y. Yu, Susan Ellard, Sebastién J. Hotte et al. · Investigational New Drugs · 2017 · 45 citations

Medicine, Oncology, Pharmacology +16

A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC).

Kim N., Sebastién J. Hotte, Susan Ellard et al. · Journal of Clinical Oncology · 2012 · 29 citations

Medicine, Oncology, Pharmacology +17

A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

Kim N., Sebastién J. Hotte, Susan Ellard et al. · Journal of Clinical Oncology · 2012 · 25 citations

Medicine, Oncology, Pharmacology +17